Navenibart lowers hereditary angioedema attack rate across ages, BMIs, baseline rates

Among adults with hereditary angioedema, navenibart lowered the rate of monthly attacks regardless of age, BMI and baseline attack rate, according to post hoc analysis findings.These data on navenibart (BioCryst), “an investigational long-acting monoclonal antibody inhibitor of plasma kallikrein,” were presented at the 2026 European Academy of Allergy and Clinical Immunology Annual